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Prophylaxis with human serum butyrylcholinesterase protects guinea pigs
exposed to multiple lethal doses of soman or VX§
Ashima Saxena a,1,*, Wei Sun a,1, James M. Fedorko a, Irwin Koplovitz b, Bhupendra P. Doctor a
aDivision of Biochemistry, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA
bDrug Assessment Division, US Army Medical Research Institute of Chemical Defense, Aberdeen Proving Ground, MD 21010, USA
1. Introduction
Organophosphorus (OP) nerve agents such as soman (GD),
sarin, VX, and tabun, exert toxicity by inhibiting acetylcholines-
terase (AChE) in the peripheral and central nervous systems (CNS).
The resultant increase in acetylcholine levels at cholinergic
synapses produces an acute cholinergic crisis; if left untreated it
can ultimately lead to death due to respiratory failure, caused by
effects at central (loss of respiratory drive) and/or peripheral
(weakness at diaphragm and intercostals muscles) systems [1].
Current medical countermeasures against OP nerve agent poison-
ing include a combination of pretreatment with a carbamate,
pyridostigmine bromide, to protect a fraction of AChE from
irreversible inhibition by OPs, followed by post-exposure treat-
ment with anticholinergic drugs such as atropine sulfate to
counteract the effects of excess acetylcholine, and oximes such as
2-PAM chloride, to reactivate OP-inhibited AChE. These antidotal
regimens are effective in preventing lethality of animals from OP
poisoning, but they do not prevent post-exposure incapacitation,
convulsions, performance deficits or in many cases, permanent
brain damage [2–4].
These problems stimulated the development of enzyme
bioscavengers as prophylactic agents to neutralize highly toxic
OP nerve agents before they reach their physiological targets [4].
Among the candidate enzymes examined, considerable progress
was made using plasma-derived cholinesterases (ChEs). Exoge-
nously administered AChE from fetal bovine serum and butyr-
ylcholinesterase (BChE; EC 3.1.1.8) from equine and human (Hu)
serum were successfully shown to prevent poisoning by OP
compounds, in both rodent and non-human primatemodels [5]. Of
these ChEs, Hu BChE is currently the most suitable enzyme for
alleviating toxicity in humans exposed to OP compounds,
including nerve agents and pesticides [6]. First, it reacts rapidly
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A B S T R A C T
Human serum butyrylcholinesterase (Hu BChE) is currently under advanced development as a
bioscavenger for the prophylaxis of organophosphorus (OP) nerve agent toxicity in humans. It is
estimated that a dose of 200 mg will be required to protect a human against 2  LD50 of soman. To
provide data for initiating an investigational new drug application for the use of this enzyme as a
bioscavenger in humans, we purified enzyme from Cohn fraction IV-4 paste and initiated safety and
efficacy evaluations in mice, guinea pigs, and non-human primates. In mice, we demonstrated that a
single dose of enzyme that is 30 times the therapeutic dose circulated in blood for at least four days and
did not cause any clinical pathology in these animals. In this study, we report the results of safety and
efficacy evaluations conducted in guinea pigs. Various doses of Hu BChE delivered by i.m. injections
peaked at 24 h and had a mean residence time of 78–103 h. Hu BChE did not exhibit any toxicity in
guinea pigs as measured by general observation, serum chemistry, hematology, and gross and
histological tissue changes. Efficacy evaluations showed that Hu BChE protected guinea pigs from an
exposure of 5.5  LD50 of soman or 8  LD50 of VX. These results provide convincing data for the
development of Hu BChE as a bioscavenger that can protect humans against all OP nerve agents.
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with highly toxic OPs, including soman, sarin, tabun, and VX.
Second, it possesses a very long retention time in human
circulation and is readily absorbed from sites of injection. Third,
multiple administrations of Hu BChE into humans are not expected
to produce any adverse immunological responses since it is a
soluble enzyme that is normally present in human circulation. Due
to the large amount of Hu BChE needed to neutralize the amount of
OP pesticide typically ingested in a case of suicide, the use of Hu
BChE as a stoichiometric bioscavenger is not practical. However, it
was shown that inclusion of fresh frozen plasma (which contains
significant amounts of Hu BChE) in the therapeutic regimen with
atropine and/or pralidoxime increased its effectiveness in pre-
venting morbidity and mortality in patients with OP pesticide
poisoning [7]. In addition to preventing OP toxicity, exogenously
administered Hu BChE was shown to be useful for alleviating
succinylcholine-induced apnea [8]. Studies in animals have also
demonstrated that the enzyme can be used for treating the toxic
effects of cocaine [9–11]. Hu BChE is a stoichiometric bioscavenger
in that 1 mol of enzyme binds to and neutralizes 1 mol of OP. A
dose of 200 mg (2.4mmol) of Hu BChE is envisioned as a
prophylactic treatment in humans that can protect from exposure
of up to 2  LD50 of soman [12].
The foremost requirement to advance Hu BChE as a biosca-
venger for human use was to obtain sufficient amounts of purified
enzyme to provide pre-clinical pharmacological information for
conducting phase I clinical trials of Hu BChE in humans. Toward
this effort, we developed a procedure for the pilot-scale manufac-
ture of Hu BChE from Cohn fraction IV-4 paste, which yielded 6–7 g
(4.3–5 million U) of purified enzyme from 80 kg of Cohn fraction
IV-4 paste [13]. The enzymewas>97% pure as judged by a specific
activity of 700 U/mg and a major band on SDS-PAGE. However,
prior to the first-dose-in-man studies, the safety of Hu BChE had to
be assessed in two animal models to identify or characterize any
secondary unwanted pharmacological or toxicological effects,
which could influence organ functions in humans. Furthermore,
results of pharmacokinetic studies and in vitro stability of the
enzyme will provide valuable guidelines for its dose design and
storage shelf-life. Therefore, the pharmacokinetics as well as safety
of purified Hu BChE were first investigated in mice [14]. In mice
administeredwith various doses of up to 90 mg/kg (1.08 mmol/kg),
enzyme activity reached peak levels in circulation at 10 h and 24 h
following i.p. and i.m. injections, respectively. The enzyme
displayed a mean residence time (MRT) of 40–50 h, regardless
of the route of injection or dose of injected enzyme. Also, Hu BChE
did not exhibit any systemic toxicity in mice as measured by
general observation, serum chemistry, hematology, and gross and
histological tissue changes. The behavioral safety of a large dose of
Hu BChE was evaluated by Clark et al. [15] who exposed mice to
2000 U (34.3 nmol) of Hu BChE (30 times the dose required for
protecting humans from 2  LD50 of soman) followed by an
assessment of acoustic startle reactivity (ASR) and prepulse
inhibition (PPI). They demonstrated that a 600-fold increase in
BChE activity in circulation did not alter ASR or PPI behavior.
As a continuation of this effort, we examined the pharmacoki-
netics and safety of large doses of Hu BChE in guinea pigs. Guinea
pigs were administered 3–60 mg/kg of Hu BChE by i.m. injection
and blood was sampled at various time intervals to characterize
the pharmacokinetics of Hu BChE. The safety of Hu BChE was
assessed by general observation, serum chemistry and hematology
as well as gross and histological tissue analyses. The efficacy of the
enzyme was also evaluated against at least 5  LD50 of soman or
VX. Results showed that Hu BChE delivered by i.m. injection
displayed long-lasting circulatory stability and did not exhibit any
toxicity in guinea pigs. All animals survived the 5.5  LD50 soman
challenge while most animals survived the 8  LD50 VX challenge.
These results provide convincing data for the development of Hu
BChE as a bioscavenger that can protect humans against all OP
nerve agents.
2. Materials and methods
All animal studies were conducted in compliance with the
Animal Welfare Act and other federal statutes and regulations
stated in the Guide for the Care and Use of Laboratory Animals
(NRC Publication, 1996 edition). All procedures with animals
received prior approval from Walter Reed Army Institute of
Research (WRAIR)/Naval Medical Research Center (NMRC) or US
ArmyMedical Research Institute of Chemical Defense (USAMRICD)
Institutional Animal Care and Use Committee and were performed
in facilities fully accredited by the Association for Assessment and
Accreditation of Laboratory Animal Care, International.
2.1. Materials
All reagent grade chemicals including butyrylthiocholine (BTC),
5,5-dithiobisnitrobenzoic acid (DTNB), and procainamide hydro-
chloride were purchased from Sigma Chemical Co. (St. Louis, MO).
Hu BChE was isolated from Cohn fraction IV-4 paste [13] and
stored in lyophilized form at 20 8C. Nerve agents soman and VX
were obtained from the U.S. Army Edgewood Chemical and
Biological Center, Aberdeen Proving Ground, MD. The purity of all
nerve agents was >98.5% as determined by 31P NMR.
2.2. Pharmacokinetics of Hu BChE in guinea pigs
These studieswere conducted atWRAIR. Dunkin Hartley guinea
pigs (Cavia porcellus) weighing 300–450 g were obtained from
Charles River Laboratories (Kingston, NY). Guinea pigs (n = 6; equal
number of males and females) were administered Hu BChE at
doses of 3, 30, or 60 mg/kg (36, 360, or 720 nmol/kg) by i.m.
injection. Following enzyme administration, 10 ml of blood was
drawn from the ear vein at various time intervals and diluted 20
times withwater for the determination of blood BChE activity [16].
The following pharmacokinetic parameters were determined from
the time course curve of blood BChE concentration: MRT, maximal
concentration (Cmax), time to reach the maximal concentration
(Tmax), elimination half-life (T1/2), and area under the plasma
concentration time curve extrapolated to infinity (AUC), using a
Windows-based program for non-compartmental analysis of
pharmacokinetic data [17].
2.3. Safety of Hu BChE in guinea pigs
Guinea pigs (n = 6; equal number of males and females) were
administered either saline or Hu BChE at a dose of 60 mg/kg
(720 nmol/kg) by i.m. or i.p. injection. Following the administra-
tion of saline or Hu BChE, animals were observed for any abnormal
physiological or behavioral signs for 14 days. The animals were
euthanized and blood was collected for determining hematology
and serum chemistry parameters. All parameter values were
expressed as mean  S.E.M. Statistical evaluation of values was
performed using an unpaired t-test (comparison of different groups)
and p values  0.05 were taken as being statistically significant.
Following blood collection, a complete necropsywas performed and a
full set of tissues, including brain, heart, lung, liver, intestine, kidney,
eye, spleen, and muscle injection sites, were examined for any gross
or histological changes.
2.4. Efficacy of Hu BChE in guinea pigs
These studies were conducted at USAMRICD. The efficacy of Hu
BChE was evaluated in guinea pigs as described [18]. Male Dunkin
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Hartley guinea pigs (n = 10) were pretreated with sufficient
quantity of Hu BChE to neutralize an 8  LD50 challenge of soman
or VX, by i.m. injection. Blood samples were drawn via toe clip at
18–20 h post enzyme administration for the determination of
BChE activity [16]. Within 15 min, animals were challenged with
1.5  LD50 of soman (1  LD50 = 30 mg/kg (165 nmol/kg)) by s.c.
injection. All animals were observed for signs of intoxication for
90 min, after which a second blood sample was taken for the
determination of blood BChE activity. On the basis of circulating
BChE activity, the animals were challenged with another 2  LD50
of soman by s.c. injection. Again, the animals were observed for
90 min, and if no signs of intoxication were observed, another
blood sample was drawn for the determination of BChE activity
and the animals were challengedwith 2  LD50 of soman onemore
time for a total challenge of 5.5  LD50. Ninety minutes following
the third challenge with soman, a final blood sample was taken for
the analysis of BChE activity and the surviving animals were held
for observation. One-half of the animals were randomly eutha-
nized after 7 days and the remaining animals were euthanized 14
days post-nerve agent challenge, for the examination of tissues by
light microscopy.
A similar paradigm was used for determining the efficacy of Hu
BChE against VX (1  LD50 = 9mg/kg (34 nmol/kg)), except that the
animals were sequentially challenged with 2.0, 2.0, and 1.0  LD50
of VX by s.c. injection for a total challenge of 5.0  LD50 on the first
day. Twenty hours following the third challenge with VX, blood
was drawn for the analysis of BChE activity. Animals were again
challenged with 1.5  LD50 of VX by s.c. injection. All animals were
observed for signs of intoxication for 90 min, after which a second
blood sample was taken for the determination of blood BChE
activity. On the basis of circulating BChE activity, the animals were
challenged with another 1.5  LD50 of VX by s.c. injection. Blood
samples were taken at 24 h and 48 h following the last challenge
with VX for the analysis of BChE activity. The surviving animals
were euthanized 7 days post-nerve agent challenge and tissues
were examined by light microscopy.
3. Results
3.1. Pharmacokinetics and safety of Hu BChE in guinea pigs
Time courses of three doses of Hu BChE administered into
guinea pigs by i.m. injection are shown in Fig. 1 and the calculated
pharmacokinetic parameters are shown in Table 1. Guinea pigs
that were administered 3, 30 or 60 mg/kg of Hu BChE by i.m.
injection showed a rapid increase in BChE activity, which reached
peak levels at 24 h. The enzyme was highly stable in circulation
and displayed an MRT of 78–110 h.
The safety of Hu BChE was evaluated in guinea pigs that were
administered 60 mg (720 nmol)/kg of enzyme. Guinea pigs with
circulating levels of BChE as high as 260 U (4.46 nmol)/ml did not
display any signs of clinical toxicity. All guinea pigs appeared in
good health and gained an average body weight of 67  5 g (saline
group), 67  10 g (Hu BChE, i.p. group) and 69  10 g (Hu BChE, i.m.
group) during the experimental period. Animals were euthanized
after two weeks post-Hu BChE injection and blood samples were
examined for hematology (Table 2) and serum chemistry parameters
(Table 3). All hematology and serum chemistry parameters measured
were within the reported normal physiological ranges [19]. There
were no significant clinical differences between saline and Hu BChE
treated groups as indicated by p values >0.05, except for RBC, HGB,
HCT, MCHC and ALP, which showed p values between 0.001 and 0.02.
The values for RBC, HGB, HCT, MCHC, and ALP were in the normal
physiological ranges for all groups, suggesting that these differences
are not biologically relevant. A complete necropsy was also
performed and a full set of tissues, including brain, heart, lung, liver,
intestine, kidney, eye, spleen, and muscle injection sites, were
examined for any gross or histological changes. No lesions or other
evidence of histopathology were observed in any subjects treated
with Hu BChE. Results of necropsy together with hematology and
serum chemistry parameters did not reveal any clinical signs of
pathology in these animals that received a large dose of Hu BChE.
3.2. Efficacy of Hu BChE in guinea pigs
The efficacy of Hu BChE was evaluated in guinea pigs against
multiple LD50 challenges of soman or VX. Guinea pigs were
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Fig. 1. Average enzyme activity in the blood of guinea pigs following injections of
Hu BChE. Animals in each group (n = 6) were delivered 3 mg/kg (~), 30 mg/kg (&),
or 60 mg/kg (*) of Hu BChE by i.m. injection. Animals injectedwith saline served as
controls (data not shown). Following enzyme administration, 10 ml of blood was
drawn at various time intervals for the determination of blood BChE activity [16].
Table 1
Pharmacokinetic parameters of Hu BChE in guinea pigsa.
Parameters Dose (mg/kg)
3 30 60
Cmax (U/ml) 10.3 0.3 101.55.8 257.912.4
MRT (h) 735 986 1033
AUC1 (Uhml1) 105020 11,270490 34,2002050
Tmax (h) 24 24 24
a Hu BChE was administered by i.m. injection.
Table 2
Hematological profiles of guinea pigs following administration of Hu BChE.
Parameters Saline Hu BChE
(60mg/kg, i.p.)
Hu BChE
(60mg/kg, i.m.)
WBC (103/ml) 4.00.3 4.50.5 4.20.5
RBC (106/ml) 5.00.1 5.50.1* 5.50.1*
HGB (g/dl) 140.3 150.2* 150.4*
HCT (%) 410.8 450.6* 461.4*
MCV (fl) 810.8 820.4 841.3
MCH (pg) 280.4 280.2 280.5
MCHC (g/dl) 340.1 340.2 330.1*
RDW (%) 9.20.1 9.30.2 9.10.2
PLT (103/ml) 29455 31055 21726
MPV (fl) 7.80.3 7.80.4 7.90.2
PCT (%) 0.220.04 0.240.04 0.170.02
PDW (%) 12.10.9 11.91.0 12.60.5
Values are mean S.E.M. WBC, white blood count; RBC, red blood cell count; HGB,
hemoglobin; HCT, hematocrit; MCV, mean corpuscular volume; MCH, mean
corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration;
RDW, red cell distribution width; PLT, platelet count; MPV, mean platelet volume;
PCT, plateletcrit; PDW, platelet volume distribution width.
* p values0.05 between saline and Hu BChE treated groups.
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pretreated with an amount of Hu BChE that would protect them
from an exposure to 8  LD50 of agent and challenged with soman
or VX, 18–20 h later. The sequential challenge design allowed us to
conduct an in vivo titration of circulating Hu BChE with the nerve
agent used for challenge. As shown in Fig. 2, there was a decrease
in molar concentration of circulating Hu BChE activity equivalent
to the amount of soman administered at a given time period. For
example, guinea pigs administered with Hu BChE sufficient to
provide protection against 8  LD50 of soman attained peak blood
BChE levels of approximately 300 U (5.14 nmol)/ml and the
enzyme level was reduced to approximately 100 U (1.7 nmol)/
ml following challenge with 5.5  LD50 of soman. This decrease of
200 U (3.4 nmol)/ml in blood BChE level corresponds to the
amount of enzyme required to neutralize 5.0–5.5  LD50 of
soman. No signs of OP poisoning were observed in animals that
were pretreated with Hu BChE and all animals survived the
duration of challenge. Animals were subjected to necropsy 7 or 14
days following nerve agent challenge and all tissues appeared
normal upon light microscopic examination.
With VX challenge, less enzyme was administered since the
LD50 of VX is lower than that for soman. The animals were
sequentially challenged with 2.0, 2.0, and 1.0  LD50 of VX for a
total challenge of 5  LD50, at 19 h post-administration of Hu
BChE. Six of 9 animals showed transient mild symptoms such as
abnormal chewing. The animals appeared healthy next morning,
and were sequentially challenged with 1.5  LD50 of VX twice for a
total challenge of 3  LD50. No signs of OP poisoningwere observed
after the first 1.5  LD50 challenge; two animals showed local
tremors, lacrimation, salivation, and crossed limbs following the
second 1.5  LD50 challenge. One animal was euthanized due to
excessive weight loss; results of necropsy revealed a small gastric
lesion, but all other tissues appeared normal upon light
microscopic examination. Eight animals survived the 8  LD50
challenge of VX; animalswere subjected to necropsy and all tissues
appeared normal upon light microscopic examination in seven
animals. Neuronal necrosis was observed in the hippocampus of
the animal that showed cholinergic symptoms following the last
VX challenge.
The decrease in circulating BChE activity following each
challenge is shown in Fig. 3. Guinea pigs administered with Hu
BChE that was sufficient to provide protection against 8  LD50 of
VX attained peak blood BChE levels of approximately 110 U
(1.9 nmol)/ml and enzyme activity was reduced to approximately
50 U (0.86 nmol)/ml following challengewith 4.0  LD50 of VX. The
animals were observed overnight following the third VX challenge,
which also resulted in a redistribution of enzyme activity from
tissues into circulation. The activity of 70 U (1.2 nmol)/ml was
reduced to 36 U (0.62 nmol)/ml following the last VX challenge
andwas25 U (0.43 nmol)/mlwhen the animalswere euthanized.
4. Discussion
Hu BChE is currently under advanced development as a
bioscavenger for the prophylaxis of OP nerve agent toxicity in
humans. It is estimated that a dose of 200 mg (2400 nmol) will be
required to protect a human against 2  LD50 of soman [12]. To
advance Hu BChE as a bioscavenger for human use, we isolated 6–
7 g (4.3–5 million U) of highly purified enzyme from 80 kg of Cohn
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Fig. 2. In vivo titration of blood-BChE activity in guinea pigs pretreatedwith Hu BChE
and challenged with soman. Guinea pigs were pretreated with Hu BChE by i.m.
injection and titrations were initiated after 18 h, in accordancewith the time profiles
of blood BChE activity shown in Fig. 1. Consecutive s.c. challenges with 1.5, 2.0, and
2.0 LD50 of soman were administered at 90 min intervals for a total challenge of
5.5 LD50. Blood BChE activity assayed prior to each challenge is shown.
Table 3
Serum chemistry profiles of guinea pigs following administration of Hu BChE.
Parameters Saline Hu BChE
(60mg/kg, i.p.)
Hu BChE
(60mg/kg, i.m.)
Metabolism & renal function
Calcium (mg/dl) 10.10.4 10.3 0.5 10.00.6
Carbon dioxide (mmol/l) 241 223 233
Chloride (mmol/l) 1031 1011 1063
Creatinine (mg/dl) 0.40.0 0.4 0.0 0.50.0
Phosphorus (mg/dl) 8.60.5 7.81.1 7.40.6
Sodium (mmol/l) 1361 1341 1434
Urea nitrogen (mg/dl) 15.61 15.01 14.51
Lipid profile
Triglycerides (mg/dl) 10222 8510 8019
Cholesterol (mg/dl) 534 513 528
Liver function
Albumin (g/dl) 1.90.1 1.9 0.1 2.10.2
ALP (U/l) 1046 1175 1324*
ALT (U/l) 8623 5310 483
AST (U/l) 27592 15469 9928
GGT (U/l) 385 619 455
LDH (U/l) 1187272 1292115 106853
Total bili (mg/dl) 0.50.1 0.5 0.0 0.50.1
Total protein (g/dl) 4.30.2 4.5 0.1 4.60.2
Other
CK (U/l) 31124 32072 40377
Values are mean S.E.M. ALP, alkaline phosphatase; ALT, alanine aminotransferase;
AST, aspartate aminotransferase; BUN, blood urea nitrogen; CK, creatine kinase; GGT,
gamma-glutamyl transpeptidase; LDH, lactate dehydrogenase.
* p value0.05 between saline and Hu BChE treated group.
[(Fig._3)TD$FIG]
15 25 35 45 55 65 75 85
0
50
100
150
200
8.0             LD
50
2.0 4.0 5.0 6.5
Time post-Hu BChE Injection, h
B
C
h
E
, U
/m
l
Fig. 3. In vivo titration of blood-BChE activity in guinea pigs pretreated with Hu
BChE and challenged with VX. Guinea pigs were pretreated with Hu BChE by i.m.
injection and titrations were initiated after 19 h. Consecutive s.c. challenges with
2.0, 2.0, and 1.0  LD50 of VX were administered at 90 min intervals for a total
challenge of 5.0  LD50 on the first day. Twenty hours following the third challenge
with VX, blood was drawn for the analysis of BChE activity and the animals were
sequentially challenged with 1.5  LD50 of VX twice for an additional challenge of
3  LD50. The cumulative challenge over a 24 h period was 8  LD50. Blood BChE
activity assayed prior to each challenge is shown.
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fraction IV-4 paste [13]. To demonstrate that Hu BChE purified
according to our procedure could function as a bioscavenger in
animals and humans, we evaluated its circulatory stability, safety,
and efficacy in two animal models. Results of pharmacokinetic
studies as well as physiological and behavioral safety evaluations
in mice demonstrated that Hu BChE displayed long-lasting
stability in circulation and was not toxic to animals [14,15]. As
a continuation of this effort, here we extended the pharmacoki-
netic and safety evaluations in guinea pigs. In addition, we
demonstrated for the first time the efficacy of Hu BChE against
5.5  LD50 of soman and 8  LD50 of VX.
Indeed, doses of 3–60 mg (36–720 nmol)/kg of Hu BChE
administered into guinea pigs by i.m. injection displayed a
pharmacokinetic profile similar to that observed previously in
rats and mice [14,20], guinea pigs [18,21], and rhesus monkeys
[22,23]. The prolonged circulatory stability of the enzyme observed
in guinea pigs (MRT = 78–110 h) is consistentwith that observed in
mice (MRT = 48 h) and monkeys (MRT = 72–74 h) [24]. A dose of
60 mg (720 nmol)/kg of Hu BChE is sufficient for protecting guinea
pigs from an exposure to 5  LD50 of soman and is 20 times the
human dose of 3 mg (36 nmol)/kg, which is predicted to provide
protection from 2  LD50 of soman [12]. All guinea pigs with
circulating activity of BChE as high as 260 U (4.46 nmol)/ml
displayed no signs of clinical toxicity or pathology. These results
are consistent with those reported in mice [14]. In addition, Hu
BChE did not display any effects on behavioral tasks inmice as well
as monkeys [15,23]. Taken together, these results suggest that Hu
BChE is devoid of any significant systemic or behavioral toxicity.
Due to the limited availability of purified Hu BChE, most
previous studies examined the efficacy of Hu BChE against 2–
3  LD50 of OP nerve agents [22,25,26]. In this study, the efficacy of
Hu BChE was evaluated in guinea pigs against multiple LD50
challenges of soman or VX using a sequential challenge design,
which allowed us to conduct an in vivo titration of circulating Hu
BChE with the nerve agent used for challenge. In each case, the
dose of enzyme administered was sufficient to neutralize 8  LD50
of agent and the decrease in blood BChE activity following each
challenge corresponds to the amount of enzyme required to
neutralize the dose of OP nerve agent. A total challenge with
5.5  LD50 of soman neutralized two-thirds of circulating Hu BChE
activity and the remaining activity was sufficient to neutralize an
additional 2.5  LD50 of soman. The stoichiometric protection by
the enzyme was demonstrated in the study with VX in which the
animals were challenged five times over a period of 24 h, for a total
challenge of 8  LD50. Previously, Raveh et al., had reported that
fetal bovine serum AChE protected mice against 8  LD50 of 7-
(methylethoxyphosphinyloxy)-1-methyl-quinolinium iodide
(MEPQ), an analog of VX [27]. This is the first study demonstrating
the ability of Hu BChE to protect from an exposure of 8  LD50 of
VX. Although pretreatment with Hu BChE provided symptom-free
protection to all 10 animals challengedwith soman, 8 of 10 animals
challenged with 8  LD50 of VX were protected. Also, animals
displayed mild transient cholinergic symptoms, such as chewing,
when the VX challenge exceeded 4  LD50. This could be due to two
reasons: (1) the rate of inhibition of Hu BChE by VX is 4–5-fold
slower as compared to AChE [20], which would result in some
inhibition of peripheral AChE by VX before itwas neutralized byHu
BChE; (2) the degradation of VX in vivo is slower as compared to G-
agents [28,29], which would prolong its time in circulation and
increase its chance of inhibiting peripheral AChE. Despite these
limitations, as shown in Fig. 3, Hu BChEwas able to neutralize high
doses of VX in circulation. These results clearly demonstrate that
Hu BChE can function as an effective stoichiometric bioscavenger
for high doses of both G- and V-type of nerve agents. This is also
supported by results of lightmicroscopic examination of all tissues
following nerve agent challenge. Taken together, these results
provide convincing data for the development of Hu BChE as a
bioscavenger that can protect humans against all OP nerve agents.
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